Study guide
3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
Board Certified Ambulatory Care Pharmacist BCACP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Patient Care Process
1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence
2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia
2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons
3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation
3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
4 Chapter 4: Endocrine & Metabolic Disorders
4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing
5 Chapter 5: Respiratory Care & Pulmonology
5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling
6 Chapter 6: Renal, Urological & Reproductive Health
6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity
7 Chapter 7: Neuropsychiatry & Behavioral Health
7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders
8 Chapter 8: Pain Management & Rheumatology
8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy
9 Chapter 9: Infectious Diseases & Immunizations
9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations
10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety
10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety
11 Chapter 11: Biostatistics, Study Design & Literature Evaluation
11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics
12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery
12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest
3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
Key Takeaways Explain This Topic AI
In non-valvular atrial fibrillation, direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin based on superior safety profiles, lower intracranial hemorrhage rates, and non-inferior or superior stroke prevention.
Apixaban dose reduction from 5 mg BID to 2.5 mg BID for non-valvular AF requires meeting at least two of three criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL; meeting only one criterion mandates maintaining full-dose 5 mg BID.
Warfarin remains the mandatory anticoagulant of choice (DOACs contraindicated) for patients with mechanical prosthetic heart valves, moderate-to-severe rheumatic mitral stenosis, and triple-positive antiphospholipid syndrome (APS).
Routine heparin bridging during elective DOAC interruption is contraindicated because it significantly increases major bleeding without reducing thromboembolic risk; interruption intervals are determined by procedural bleeding risk and patient renal function.
Specific reversal agents include idarucizumab (Praxbind) for dabigatran, andexanet alfa (Andexxa) for apixaban and rivaroxaban, and 4-factor prothrombin complex concentrate (4F-PCC / Kcentra) with intravenous vitamin K for life-threatening warfarin-associated bleeding.
Last updated: September 2026
3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
BCACP Exam Anchor: Anticoagulation management spans a major portion of ambulatory clinical pharmacy practice. Exam candidates must master CHA 2 DS 2 -VASc \text{CHA}_2\text{DS}_2\text{-VASc} CHA 2 DS 2 -VASc point scoring thresholds, precise DOAC renal and clinical dose-reduction rules (specifically the apixaban "2 of 3 ABC" rule and edoxaban upper CrCl cutoff), mandatory warfarin indications, evidence-based peri-procedural interruption schedules, and immediate reversal protocols for life-threatening hemorrhage.
Stroke & Bleeding Risk Stratification in Atrial Fibrillation
In patients with non-valvular atrial fibrillation (AF), antithrombotic selection is guided by calculating the CHA 2 DS 2 -VASc \text{CHA}_2\text{DS}_2\text{-VASc} CHA 2 DS 2 -VASc stroke risk score and assessing modifiable bleeding risks via the HAS-BLED score.
The CHA 2 DS 2 -VASc \text{CHA}_2\text{DS}_2\text{-VASc} CHA 2 DS 2 -VASc Scoring System
- Risk Factor Definition Points Assigned
- C Congestive Heart Failure (or LVEF ≤40%) 1
- H Hypertension (or on antihypertensive therapy) 1
- A 2 _2 2 Age ≥ 75 \ge 75 ≥ 75 years 2
- D Diabetes Mellitus (Type 1 or Type 2) 1
- S 2 _2 2 Prior Stroke, TIA, or Thromboembolism 2
- V Vascular Disease (prior MI, peripheral artery disease, or complex aortic plaque) 1
- A Age 65 to 74 years 1
- Sc Sex Category: Female 1
- Maximum Total Score 9
- Guideline Decision Thresholds
Score ≥ 2 \ge 2 ≥ 2 in Men or ≥ 3 \ge 3 ≥ 3 in Women (Class 1 Recommendation): Oral anticoagulation is strongly recommended. Direct oral anticoagulants (DOACs) are preferred over warfarin.
Score of 1 in Men or 2 in Women (Class 2b Recommendation): Oral anticoagulation may be considered based on shared clinical decision-making.
Score of 0 in Men or 1 in Women (Class 3 / No Benefit): Omit all antithrombotic therapy. Clinical Pearl: Aspirin monotherapy is not recommended for stroke prevention in AF because it provides negligible stroke reduction while carrying substantial bleeding risk.
Bleeding Risk Assessment: HAS-BLED Score
Evaluates: H ypertension (SBP > 160 >160 > 160 ), A bnormal renal/liver function (1 pt each), S troke history, B leeding history/predisposition, L abile INRs, E lderly ( > 65 >65 > 65 ), D rugs/Alcohol (antiplatelets, NSAIDs, alcohol excess; 1 pt each).
Clinical Rule: A high HAS-BLED score ( ≥ 3 \ge 3 ≥ 3 ) is not a reason to withhold oral anticoagulation . Instead, it alerts the clinician to identify and remediate modifiable bleeding risk factors (uncontrolled blood pressure, concurrent NSAID use, alcohol misuse, and labile INR).
Direct Oral Anticoagulants (DOACs): Dosing & Adjustments
DOACs represent the standard of care for non-valvular atrial fibrillation and venous thromboembolism (VTE: DVT and PE) due to fixed dosing, lack of routine INR monitoring, minimal food interactions, and significantly lower rates of life-threatening intracranial hemorrhage compared to warfarin.
Drug Direct Target Non-Valvular AF Dosing VTE Initial Treatment Extended VTE Secondary Prevention Renal Cutoffs & Critical Clinical Pearls
Apixaban (Eliquis) Factor Xa 5 mg PO BID ; (Dose reduce to 2.5 mg BID if 2 of 3 criteria met) 10 mg PO BID × \times × 7 days , then 5 mg PO BID 2.5 mg PO BID (after ≥6 months of full-dose VTE treatment) The "2 of 3 ABC Rule" in AF: Dose reduce to 2.5 mg BID ONLY if patient meets ≥ 2 \ge 2 ≥ 2 of: A ge ≥ 80 yr \ge 80\text{ yr} ≥ 80 yr , B ody weight ≤ 60 kg \le 60\text{ kg} ≤ 60 kg , or C reatinine (Serum Creatinine ≥ 1.5 mg/dL \ge 1.5\text{ mg/dL} ≥ 1.5 mg/dL ). If only 1 criterion is met, give 5 mg BID! No parenthetical lead-in required for VTE.
Rivaroxaban (Xarelto) Factor Xa 20 mg PO QD with evening meal ; (CrCl 15–50: 15 mg QD with food) 15 mg PO BID with food × \times × 21 days , then 20 mg PO QD with food 10 mg PO QD with food (or 20 mg QD) Food Effect: The 15 mg and 20 mg tablets must be taken with food (fat/caloric intake boosts bioavailability from 66% to ~100%). Avoid if CrCl < 15 mL/min \text{CrCl} < 15\text{ mL/min} CrCl < 15 mL/min . No parenteral lead-in required.
Dabigatran (Pradaxa) Direct Thrombin (Factor IIa) 150 mg PO BID ; (CrCl 15–30: 75 mg BID) 150 mg PO BID (AFTER 5–10 days of parenteral anticoagulation) 150 mg PO BID Parenteral Lead-In: Requires 5–10 days of IV UFH or SC LMWH before starting dabigatran for VTE.; Handling: Keep in original desiccant bottle ; discard 120 days after opening. Swallow capsules whole (opening increases bioavailability by 75%, causing bleeding). High dyspepsia rate (~10%).
Edoxaban (Savaysa) Factor Xa 60 mg PO QD ; (CrCl 15–50 or wt ≤60 kg: 30 mg QD) 60 mg PO QD (AFTER 5–10 days of parenteral anticoagulation) 60 mg PO QD Black Box Warning / Upper Cutoff: Do NOT use in non-valvular AF if CrCl > 95 mL/min \text{CrCl} > 95\text{ mL/min} CrCl > 95 mL/min because excessive renal clearance reduces drug exposure, leading to increased ischemic stroke rates compared to warfarin (ENGAGE AF-TIMI 48 trial). Requires 5–10 days parenteral lead-in for VTE.
Warfarin Pharmacotherapy & Mandatory Indications
Warfarin acts as an antagonist of vitamin K epoxide reductase complex 1 (VKORC1) , inhibiting the γ \gamma γ -carboxylation of vitamin K-dependent clotting factors ( II, VII, IX, X ) and natural regulatory anticoagulant proteins C and S .
Mandatory Clinical Indications for Warfarin (DOACs Contraindicated!)
Major randomized trials have established that DOACs are either ineffective or hazardous in specific conditions where warfarin remains the mandatory gold standard:
Mechanical Prosthetic Heart Valves: The RE-ALIGN trial demonstrated that dabigatran caused excess thromboembolic events (valve thrombosis, stroke) and major bleeding compared to warfarin. DOACs are strictly contraindicated with all mechanical heart valves.
Mechanical Mitral Valve: Target INR 2.5 to 3.5 .
Mechanical Aortic Valve: Target INR 2.0 to 3.0 (Target 2.5 to 3.5 if additional risk factors present: AF, prior thromboembolism, LV dysfunction, or older-generation caged-ball/tilting-disc valve).
Bioprosthetic Valves: Warfarin target INR 2.0 to 3.0 for the initial 3 to 6 months post-implantation, after which DOACs or aspirin may be used.
Moderate-to-Severe Rheumatic Mitral Stenosis: DOACs are not approved; warfarin is required with target INR 2.0 to 3.0 .
Triple-Positive Antiphospholipid Syndrome (APS): The TRAPS trial demonstrated an excess of arterial thromboembolic events (stroke, MI) with rivaroxaban compared to warfarin in patients positive for all 3 antibodies (lupus anticoagulant, anticardiolipin, and anti- β 2 \beta_2 β 2 -glycoprotein I). Warfarin with target INR 2.0 to 3.0 is mandatory.
Warfarin Initiation & Acute VTE Bridging Protocol
The Protein C/S Depletion Paradox: Factor VII (half-life ~6 hours) and Protein C (half-life ~8 hours) decline rapidly upon starting warfarin, while Factor II (prothrombin, half-life ~60–72 hours) declines slowly. This creates a transient, paradoxical hypercoagulable state during the first 24 to 48 hours.
VTE Bridging Rule: In acute VTE, warfarin must be overlapped with a therapeutic parenteral anticoagulant (enoxaparin 1 mg/kg SC q12h, dalteparin, or IV UFH) for a minimum of 5 full days AND until the INR is ≥ 2.0 \ge 2.0 ≥ 2.0 for at least 24 consecutive hours (two therapeutic INRs 24 hours apart).
Critical Drug & Dietary Interactions
CYP2C9 Inhibitors (Dramatically Increase INR / Bleeding Risk): Amiodarone , Fluconazole , Metronidazole , and Trimethoprim-Sulfamethoxazole (Bactrim) . When initiating amiodarone, metronidazole, or Bactrim in a patient on stable warfarin, empirically decrease the warfarin maintenance dose by 30% to 50% and monitor INR in 3 to 5 days.
CYP2C9 / CYP3A4 Inducers (Decrease INR / Thrombosis Risk): Rifampin, carbamazepine, phenobarbital, phenytoin, St. John's wort.
Dietary Vitamin K: Green leafy vegetables (spinach, kale, collard greens, broccoli). Patients must be counseled on consistent weekly intake rather than strict avoidance.
Peri-Procedural Anticoagulation Management
Managing anticoagulation before elective invasive procedures requires balancing thromboembolic risk during interruption against procedural bleeding risk.
- Elective DOAC Interruption Schedule Elective Surgical / Invasive Procedure
- │
- ┌──────────────────────────────────┴──────────────────────────────────┐
- ▼ ▼
- Low Bleeding Risk Procedure High Bleeding Risk Procedure
- (Minor dental, skin excision, cataract) (Major surgery, spinal/epidural, cardiac)
- │ │
- Hold DOAC 24 Hours Assess Renal Function (CrCl)
- (1 Day Prior / 1-2 Doses) │
- │ ┌──────────────────────┴──────────────────────┐
- ▼ ▼ ▼
- Resume DOAC 24 Hours Post-Op CrCl ≥50 mL/min CrCl 30-49 mL/min
- (Once Hemostasis Secured) │ │
- Hold Apixaban / Rivaroxaban / Hold Apixaban / Rivaroxaban
- Edoxaban / Dabigatran: for 72 Hours;
- 48 Hours (2 Days Prior) Hold Dabigatran for 72-96 Hours
- │ │
- └──────────────────────┬──────────────────────┘
- │
- ▼
- *DO NOT BRIDGE WITH HEPARIN!*
- │
- ▼
- Resume Full-Dose DOAC at 48-72 Hours
- (Once Complete Hemostasis Established)
The "No Bridging for DOACs" Rule: Routine bridging with therapeutic LMWH or UFH during DOAC interruption is strictly contraindicated . Because DOACs have rapid clearance and predictable offset, bridging provides zero thromboembolic benefit while tripling major peri-procedural bleeding rates.
Warfarin Interruption & Bridging Protocol
Interruption: Discontinue warfarin 5 days prior to surgery to allow the INR to normalize to < 1.5 <1.5 < 1.5 .
Selective Bridging Indications (Therapeutic LMWH / Enoxaparin 1 mg/kg SC q12h):
High Thromboembolic Risk (Bridge!): Any mechanical mitral valve, mechanical aortic valve with additional risk factors, recent stroke/TIA within 3 months, or CHA 2 DS 2 -VASc ≥ 7 to 8 \text{CHA}_2\text{DS}_2\text{-VASc} \ge 7\text{ to } 8 CHA 2 DS 2 -VASc ≥ 7 to 8 .
Low/Moderate Thromboembolic Risk (Do NOT Bridge!): Bileaflet mechanical aortic valve without risk factors, non-valvular AF with CHA 2 DS 2 -VASc ≤ 6 \text{CHA}_2\text{DS}_2\text{-VASc} \le 6 CHA 2 DS 2 -VASc ≤ 6 , or VTE > 12 >12 > 12 months ago (the landmark BRIDGE trial proved bridging in these cohorts increases major bleeding with no reduction in stroke).
Bridging Timing: Discontinue therapeutic SC LMWH 24 hours prior to surgery (IV UFH stopped 4 to 6 hours prior). Restart LMWH 24 hours post-op for minor surgery, or 48 to 72 hours post-op for high bleeding risk surgery.
Anticoagulation Reversal & Emergency Protocols
Anticoagulant Targeted Reversal Agent Mechanism of Action Clinical Dosing & Administration
Dabigatran Idarucizumab (Praxbind) Humanized monoclonal antibody fragment (Fab) that binds free and thrombin-bound dabigatran with 350x higher affinity than thrombin 5 g IV total administered as two consecutive 2.5 g IV boluses/infusions within 15 minutes. Immediate, complete reversal.
Apixaban & Rivaroxaban Andexanet alfa (Andexxa) Recombinant modified human factor Xa decoy protein lacking catalytic activity; binds and sequesters FXa inhibitors Low Dose: 400 mg IV bolus @ 30 mg/min, followed by 4 mg/min IV infusion for up to 120 minutes.; High Dose: 800 mg IV bolus @ 30 mg/min, followed by 8 mg/min IV infusion for up to 120 minutes.; (High dose used if rivaroxaban >10 mg or apixaban >5 mg taken <8 hours ago) .
Warfarin 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Kcentra) + IV Vitamin K Contains concentrated Factors II, VII, IX, X and Proteins C & S 4F-PCC dosed by baseline INR and weight (25–50 units/kg; max 5000 units) + Phytonadione (Vitamin K) 5 to 10 mg slow IV infusion over 30 minutes in 50 mL normal saline.; (Preferred over FFP: rapid reversal <30 min, low volume, no ABO typing) .
Unfractionated Heparin (UFH) & LMWH Protamine Sulfate Strongly basic peptide that forms an inactive salt complex with acidic heparin UFH Reversal: 1 mg protamine per 100 units UFH administered in prior 2–3 hours (max single dose 50 mg; slow IV push over 10 min to avoid severe hypotension/anaphylactoid reaction).; Enoxaparin Reversal: 1 mg protamine per 1 mg enoxaparin if given within 8 hours (~60–75% anti-Xa neutralization).